← Evidence map

ArticleOncogene2007

Endoglin inhibits prostate cancer motility via activation of the ALK2-Smad1 pathway.

C S Craft et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.

30 papers cite it

2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
this papertrialcites it
Full record →Abstract, authors, funding and every citing paper · PMID 17496924